---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product comparison"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product comparison. Topics: Comparator landscape as stated by the sponsor; Trofinetide: approved indication and dosing; Trofinetide: mechanism of action and tolerability; NGN-401: construct, regulation, and route of administration; 3 further topics. 7 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description/product-comparison"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product comparison

<a id="heading-2.1.2.14"></a>

## 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

### Comparator landscape as stated by the sponsor

> “Trofinetide was approved by the FDA in March 2023 for the treatment of Rett Syndrome. We are aware that our competitors are developing product candidates for the treatment of diseases that our product candidates will target. With respect to TSHA-102, we are aware that Neurogene has a clinical stage gene therapy program for the treatment of Rett syndrome.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-2.1.2.14-2"></a>

### Trofinetide: approved indication and dosing

> “DAYBUE and DAYBUE STIX are indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.”
> “The recommended dosage of DAYBUE or DAYBUE STIX is based on patient weight as shown in Table 1. Administer DAYBUE or DAYBUE STIX orally or via gastrostomy (G) tube twice daily, in the morning and evening, with or without food.”

Source: [Acadia DAYBUE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217026s008lbl.pdf)

<a id="topic-2.1.2.14-3"></a>

### Trofinetide: mechanism of action and tolerability

> “The mechanism by which trofinetide exerts therapeutic effects in patients with Rett syndrome is unknown.”
> “85% of patients treated with DAYBUE experienced diarrhea.”
> “In those treated with DAYBUE, 49% either had persistent diarrhea or recurrence after resolution despite dose interruptions, reductions, or concomitant antidiarrheal therapy.”
> “In Study 1, vomiting occurred in 29% of patients treated with DAYBUE and in 12% of patients who received placebo”

Source: [Acadia DAYBUE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217026s008lbl.pdf)

<a id="topic-2.1.2.14-4"></a>

### NGN-401: construct, regulation, and route of administration

> “NGN-401 is an investigational AAV9 gene therapy in late-stage clinical development as a potential best-in-class, one-time treatment for Rett syndrome.”
> “NGN-401 is delivered through intracerebroventricular administration to achieve the broadest targeting directly to the brain and nervous system based on nonclinical biodistribution data.”

Source: [Neurogene third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1404644/000140464426000064/ngne_3qye26earningsrelease.htm)

<a id="topic-2.1.2.14-5"></a>

### NGN-401: registrational trial and expected data

> “Anticipate reporting topline data from the Embolden™ registrational trial in the second half of 2027”
> “Neurogene elected to include all 25 participants dosed in the primary efficacy analysis.”
> “The corresponding threshold for success to reject the null hypothesis is 9 of 25 participants (36%).”
> “NGN-401 at the 1E15 vg dose has been generally well-tolerated in the Phase 1/2 trial and Embolden (N=35) as of November 8, 2026”

Source: [Neurogene third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1404644/000140464426000064/ngne_3qye26earningsrelease.htm)

<a id="topic-2.1.2.14-6"></a>

### NGN-401: registry record of the Embolden trial

> “A Baseline-Controlled, Open-Label, Multicenter, Single-Arm, Pivotal Study to Evaluate the Efficacy, Safety, and Tolerability of NGN-401 in Subjects With Rett Syndrome (Embolden)”
> “NGN-401 is a non-replicating, recombinant AAV9 carrying a full length human MECP2 transgene.”

Source: [ClinicalTrials.gov NCT05898620](https://clinicaltrials.gov/study/NCT05898620)

<a id="topic-2.1.2.14-7"></a>

### Published comparison of TSHA-102 and NGN-401

| Feature | TSHA-102 | NGN-401 |
| --- | --- | --- |
| MECP2 construct | “Truncated miniMECP2 (MBD + NID domains only)” | “Full-length human MECP2” |
| Regulatory system | “miRARE (endogenous miRNA-responsive)” | “EXACT (synthetic miRNA feedforward loop)” |
| AAV type | “Self-complementary AAV9” | “Standard single-stranded AAV9” |
| Administration route | “Intrathecal lumbar puncture” | “Intracerebroventricular (ICV)” |
| Procedural complexity | “Moderate (lumbar puncture)” | “Higher (neurosurgical ICV access)” |
| CNS biodistribution | “Moderate (based on IT delivery)” | “Superior (10–100 × higher in preclinical NHP studies)” |
| Safety profile to date | “Favorable; no SAEs or DLTs” | “Favorable at low doses; high-dose hyperinflammatory fatality” |

Source: [Samanta (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12864443/)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
